Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab Vedotin in Elderly Relapsed/Refractory Hodgkin Lymphoma
NCT02227433Phase 2Completed
- Sponsor
- Fondazione Italiana Linfomi
- Start
- Feb 2013
- Primary completion
- Apr 2018
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of brentuximab vedotin in Hodgkin lymphoma (HL), sponsored by Fondazione Italiana Linfomi. Primary endpoint: Overall Objective Response Rate at 2 years. Started Feb 2013; status: completed.
02
Drugs
brentuximab vedotin
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT02227433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02227433.